Quarterly ResultAug 11, 2026, 07:07 AM
Neuraxis Q2 Net Sales Up 115.7% to $1.93M; Going Concern Doubt
AI Summary
Neuraxis, Inc. reported a significant increase in net sales for the second quarter of 2026, reaching $1.93 million, a 115.7% rise year-over-year. Despite this revenue growth, the company continues to incur net losses, with a net loss of $2.09 million for the quarter and $3.85 million for the six months ended June 30, 2026. The company's financial statements include a "going concern" warning, indicating substantial doubt about its ability to continue operations without additional funding, despite an improved cash position and working capital surplus.
Key Highlights
- Net sales for Q2 2026 increased 115.7% to $1,928,695 from $894,086 in Q2 2025.
- Net loss for Q2 2026 was $(2,085,746), compared to $(1,690,418) in Q2 2025.
- Basic and diluted loss per share for Q2 2026 was $(0.19), an improvement from $(0.22) in Q2 2025.
- Cash and cash equivalents increased to $8,322,258 as of June 30, 2026, from $4,965,072 at year-end 2025.
- Company issued a "going concern" warning due to continued losses and reliance on future funding.
- The Rectal Expulsion Device (RED) received FDA clearance in 2024.
- NSS-2 Bridge license with Masimo was terminated on July 1, 2025, recapturing intellectual property rights.
- Total stockholders' equity increased to $6,735,053 as of June 30, 2026, from $3,399,372 at year-end 2025.
Price Impact
More from NRXS